Crossmark

Molecular markers or clinical end points? What is the optimal monitoring tool for low-dose rituximab in membranous nephropathy in resource-limited settings?

Crossref DOI link: https://doi.org/10.1007/s40620-025-02273-x

Published Online: 2025-04-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mathew, Gerry George https://orcid.org/0000-0003-1967-4470
License Information

Text and Data Mining valid from 2025-04-07

Version of Record valid from 2025-04-07
More Information

Article History

Received: 2 December 2024

Accepted: 1 March 2025

First Online: 7 April 2025

Declarations

:

: None.

: Not applicable.

: This study does not directly involve humans or animals and it ensures adherence to the Declaration of Helsinki.

: There was no requirement for informed consent from patients since it was a manuscript by the physician based on current scientific evidence.

Document is current

Any future updates will be listed below